Relationship of Skin Related SNP to Topical Skin Care Product
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03446079|
Recruitment Status : Enrolling by invitation
First Posted : February 26, 2018
Last Update Posted : February 21, 2019
|Condition or disease||Intervention/treatment||Phase|
|Genetics Skin Aging||Other: Topical Anti Aging Cream||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||200 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||Cross sectional will utilize gene-specific candidate and genome wide association analysis to identify SNP's that may be associated with response to a topical product.|
|Masking:||None (Open Label)|
|Masking Description:||Investigators and participants will be blinded to the results genetic testing results during the trial duration. Only participants will be blinded to the identity of the study product.|
|Official Title:||Relationship of Skin Related Single Nucleotide Polymorphisms to Clinical Response to a Topical Skin Care Product|
|Actual Study Start Date :||March 19, 2018|
|Estimated Primary Completion Date :||April 19, 2020|
|Estimated Study Completion Date :||April 19, 2020|
Experimental: Primary Subjects
Male or female subjects 21 or older that meet the specified inclusion/exclusion criteria taking genetic test and applying topical anti aging cream per the protocol.
Other: Topical Anti Aging Cream
Primary Subjects will take a saliva based genetic test and apply a topical anti aging cream for 6 weeks.
Other Name: Genetic Test (for association purposes only)
- Genetic Profile & Product Response [ Time Frame: 6 weeks ]The primary endpoint being studied in this study is the association of the product response to the 17 candidate SNP genotypes.
- Novel SNP Identification [ Time Frame: 6 weeks ]The secondary endpoint will be identification of novel SNPs through genome-wide association analysis that may be associated with response to the study product.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03446079
|United States, California|
|Laguna Hills, California, United States, 92653|
|Principal Investigator:||Katherine Lee, MD, MA||Member|